Kali-Extracts and Puration Announce First Shipment Of Hemp-Derived CBD Infused Private Label Water For Pharmaceutical Client

Kali-Extracts and Puration Announce First Shipment Of Hemp-Derived CBD Infused Private Label Water For Pharmaceutical Client

Dallas, TX -- December 13, 2018 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) and Puration, Inc. (USOTC: PURA) (“PURA”) today announced shipping the first private labeled, hemp-derived CBD infused, high alkaline water to Generex Biotechnology Corporation (OTCQB: GNBT) in conjunction with a previously announced agreement to produce $1 million of CBD infused water for Generex.  PURA is producing the CBD infused water for Generex and PURA has in turn engaged KALY in a $300,000 contract to produce the CBD extract specific to the requirements of Generex. 

Kali-Extracts recently acquired a patented cannabis extraction process, that comes with a substantial volume of associated clinical research. Since the acquisition of the patented cannabis extraction process, Kali-Extracts and Puration, with two other partners, have together formed a joint venture company (JV) titled US Cannabis Health.  The purpose of the JV is to pursue partnerships with pharmaceutical companies to produce cannabis extract pharmaceutical applications. 

For more information visit:

www.kali-extracts.com
and
www.purationinc.com

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 
Puration, Inc.

Contact:

Puration, Inc.
Brian Shibley,
[e-mail]
[phone]

Kali, Inc.
Frederick Ferri
[e-mail]
[phone]